| Item 7.01 | Regulation FD Disclosure. |
On April 17, 2020, Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) will be updating its corporate overview presentation on its website, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form8-K.
The information in this Item 7.01 of this Current Report on Form8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
On April 15, 2020, Ted White, Verrica’s President & CEO, delivered a virtual presentation at the 19th Annual Needham Healthcare Conference. During the presentation, which was webcast, Mr. White provided updated information regarding Verrica’s planned clinical trials in light of theCOVID-19 pandemic. In particular, Mr. White reported that, given the current conditions related to the Coronavirus, Verrica is monitoring the situation very closely and the Company intends to launch Phase 3 clinical trials to evaluateVP-102 for common warts when conditions are appropriate. In addition, the Company also plans to launch the proposed Phase 2 clinical trial to evaluateVP-103 in subjects with plantar warts when conditions are appropriate. Prior to the pandemic and the widespread adoption of “sheltering in place” and “stay at home” orders, the Company remained on track to initiate Phase 3 trials ofVP-102 for common warts in the first half of 2020 and the Phase 2 trial ofVP-103 for plantar warts inmid-2020, as previously publicly reported.
Statements contained in this Current Report on Form8-K regarding the timing of the initiation of Verrica’s planned clinical trials constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on Verrica’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties relating to the severity, duration and spread of theCOVID-19 outbreak, as well as the direct and indirect impacts that the pandemic may have on the conditions to initiate the planned clinical trials, as well as other risks and uncertainties that are described in Verrica’s Annual Report on Form10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission on March 13, 2020, and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this report and are based on information available to Verrica as of the date of this report, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
(d) Exhibits
